Rezultati pretrage - A. W. Tolcher

  • Prikaz rezultata 1 – 3 od 3
Detaljiziraj rezultate
  1. 1
    Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

    Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors od Heather A. Wakelee, Amita Patnaik, Branimir I. Šikić, Monica Mita, N. L. Fox, R. Miceli, S J Ullrich, George A. Fisher, A. W. Tolcher

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors od Timothy A. Yap, Atish D. Choudhury, Erika Hamilton, Lee S. Rosen, Kayla Stratton, M. Gordon, David Schaer, Lei Liu, L. Zhang, Rajendar K. Mittapalli, Wei Zhong, N. Soman, A. W. Tolcher

    Izdano 2024
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

    A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high in... od Jordi Rodón, Estelamari Rodríguez, Michael L. Maitland, Frank Tsai, Mark A. Socinski, Jordan Berlin, Jacob Thomas, Tareq Al Baghdadi, I.‐M. Wang, Cunlan Guo, Mohammad‐Taghi Golmakani, Lorraine N. Clark, Mihaela Gazdoiu, Meng Li, A. W. Tolcher

    Izdano 2024
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: